Carbogen Amcis

Dishman Pharma‘s all global plants, except China, have been cleared by the US FDA, says JR Vyas, CMD of the company.

Dishman pins hopes on China unit

JR Vyas, MD, Dishman Pharma says Carbogen Amcis anticipates a turnover of 96 million this fiscal and a turnover of 106 million the next fiscal year.

FY12 profit to be better than FY11: Dishman Pharma

Dishman's Managing Director JR Vyas expects its key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in from Abbott in FY13.

Dishman Pharma eyes over 15% topline growth going forward

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

Dishman Pharma expects a 15% growth in FY12

In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.

Dishman Pharma expects 15% consolidated growth, says CFO

In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.